ARS PHARMACEUTICALS INC (SPRY) Stock Price, Quote, News and Overview
NASDAQ:SPRY - Nasdaq - US82835W1080 - Common Stock - Currency: USD
SPRY Quote, Performance and Key Statistics
14.64
+0.26 (+1.81%)
The current stock price of SPRY is 14.64 USD. In the past month the price increased by 16.19%. In the past year, price increased by 75.33%.
SPRY Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.82 | 319.07B | ||
| AMGN | AMGEN INC | 14.12 | 150.46B | ||
| GILD | GILEAD SCIENCES INC | 23.03 | 132.33B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1698.17 | 126.60B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.14 | 65.57B | ||
| ARGX | ARGENX SE - ADR | 322.85 | 36.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.56B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.98B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.60B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 27.06B | ||
| NTRA | NATERA INC | N/A | 20.88B | ||
| BIIB | BIOGEN INC | 7.26 | 17.49B |
Related stock screener links
About SPRY
Company Profile
ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. The company is headquartered in San Diego, California and currently employs 146 full-time employees. The company went IPO on 2020-12-04. The firm is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Company Info
ARS PHARMACEUTICALS INC
11682 El Camino Real, Suite 120
San Diego CALIFORNIA US
Employees: 26
Company Website: https://ars-pharma.com/
Investor Relations: https://ars-pharma.com/investors-and-media/
Phone: 18587719307
ARS PHARMACEUTICALS INC / SPRY FAQ
What is the stock price of ARS PHARMACEUTICALS INC today?
The current stock price of SPRY is 14.64 USD. The price increased by 1.81% in the last trading session.
What is the ticker symbol for ARS PHARMACEUTICALS INC stock?
The exchange symbol of ARS PHARMACEUTICALS INC is SPRY and it is listed on the Nasdaq exchange.
On which exchange is SPRY stock listed?
SPRY stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ARS PHARMACEUTICALS INC stock?
12 analysts have analysed SPRY and the average price target is 32.23 USD. This implies a price increase of 120.16% is expected in the next year compared to the current price of 14.64. Check the ARS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ARS PHARMACEUTICALS INC worth?
ARS PHARMACEUTICALS INC (SPRY) has a market capitalization of 1.44B USD. This makes SPRY a Small Cap stock.
How many employees does ARS PHARMACEUTICALS INC have?
ARS PHARMACEUTICALS INC (SPRY) currently has 26 employees.
What are the support and resistance levels for ARS PHARMACEUTICALS INC (SPRY) stock?
ARS PHARMACEUTICALS INC (SPRY) has a support level at 14.63 and a resistance level at 14.89. Check the full technical report for a detailed analysis of SPRY support and resistance levels.
Is ARS PHARMACEUTICALS INC (SPRY) expected to grow?
The Revenue of ARS PHARMACEUTICALS INC (SPRY) is expected to grow by 380.02% in the next year. Check the estimates tab for more information on the SPRY EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ARS PHARMACEUTICALS INC (SPRY) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SPRY, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SPRY, evaluating the profitability, health, valuation and growth aspects
- ARS PHARMACEUTICALS INC (SPRY) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ARS PHARMACEUTICALS INC (SPRY) Sales and EPS estimates to see what analysts future expectations are.
- ARS PHARMACEUTICALS INC (SPRY) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ARS PHARMACEUTICALS INC (SPRY) Insider and Institutional Ownership to learn about the owners and their transactions.
- ARS PHARMACEUTICALS INC (SPRY) Stock Chart to make your own analysis
- ARS PHARMACEUTICALS INC (SPRY) Latest news and press-releases to stay up to date.
Does ARS PHARMACEUTICALS INC (SPRY) stock pay dividends?
SPRY does not pay a dividend.
When does ARS PHARMACEUTICALS INC (SPRY) report earnings?
ARS PHARMACEUTICALS INC (SPRY) will report earnings on 2025-05-09, before the market open.
What is the Price/Earnings (PE) ratio of ARS PHARMACEUTICALS INC (SPRY)?
The PE ratio for ARS PHARMACEUTICALS INC (SPRY) is 292.8. This is based on the reported non-GAAP earnings per share of 0.05 and the current share price of 14.64 USD. Check the full fundamental report for a full analysis of the valuation metrics for SPRY.
What is the Short Interest ratio of ARS PHARMACEUTICALS INC (SPRY) stock?
The outstanding short interest for ARS PHARMACEUTICALS INC (SPRY) is 28.97% of its float. Check the ownership tab for more information on the SPRY short interest.
SPRY Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to SPRY. When comparing the yearly performance of all stocks, SPRY is one of the better performing stocks in the market, outperforming 95.59% of all stocks.
SPRY Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to SPRY. SPRY is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
SPRY Financial Highlights
Over the last trailing twelve months SPRY reported a non-GAAP Earnings per Share(EPS) of 0.05. The EPS increased by 108.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.97% | ||
| ROA | 2.28% | ||
| ROE | 3.11% | ||
| Debt/Equity | 0 |
SPRY Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to SPRY. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of -2867.61% and a revenue growth 380.02% for SPRY